VIE VENTURES

VIE IMPACT

Invest Broadly.
Give with Focus.

Investing in autoimmune therapeutics and growing resources for family philanthropy.

November 2026

Presented by Vie Venture Partners LLC

Important Information

Confidentiality. This presentation has been prepared solely for use by prospective investors of Immunology & Autoimmune Fund, LP, including feeder and/or parallel vehicles thereto such as Vie Impact, LP (collectively, the "Fund") and shall be maintained in strict confidence. Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of its contents, without the prior written consent of the Fund's general partner or management company (together with their affiliates, the "Sponsor") is prohibited. This presentation will be returned to the Sponsor upon request. The existence and nature of all conversations regarding the Fund must be kept confidential.

Governing Documents. This presentation has been prepared in connection with a private offering to accredited investors of limited partnership interests in the Fund (the "Interests"). Each investor will be required to execute a subscription agreement, a limited partnership agreement, and/or other definitive transaction documents to effect an investment (collectively, "Governing Documents"). If any of the terms, conditions or other provisions of the Governing Documents are inconsistent with or contrary to the descriptions or terms in this presentation, the Governing Documents shall control.

Applicable Law. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any security in any jurisdiction in which it is unlawful to make such an offer or solicitation. Neither the U.S. Securities and Exchange Commission nor any other federal, state or foreign agency has approved an investment in the Fund. Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this presentation. The Interests have not been registered under the U.S. Securities Act of 1933 or any state securities laws or the laws of any foreign jurisdiction. The Fund will not be registered as an investment company under the U.S. Investment Company Act of 1940. Consequently, investors will not be afforded the protections of the foregoing statutes.

Limitations on Information. The information set forth in this presentation does not purport to be complete and unless expressly indicated otherwise, is current as of the date on the cover of this presentation. The Sponsor assumes no obligation to update or otherwise revise the information contained in this presentation, irrespective of any new information that becomes available to the Sponsor or comes to its attention. No undertaking, representation, warranty, or other assurance, express or implied, is made or given by the Fund or the Sponsor as to the accuracy or completeness of the information or opinions contained in this presentation, and no responsibility or liability is accepted by either of them for any such information or opinions. Certain information contained herein has been obtained from other parties. While such sources are believed to be reliable, neither the Fund nor the Sponsor assumes any responsibility for the accuracy or completeness of such information. A prospective investor must rely solely on the terms of, and disclosure of information in, the Governing Documents, the only basis on which subscriptions may be made. The graphs, charts and other visual aids are provided for informational purposes only and cannot, of themselves, be used to make investment decisions. No representation is made that these will assist any person in making investment decisions and no graph, chart or other visual aid can capture all factors and variables required in making such decisions.

Performance Information and Forward-Looking Statements. In considering the prior performance information contained herein, prospective investors should bear in mind that past performance is not necessarily indicative of future results, and there can be no assurance that the Fund will achieve comparable results. Certain statements in this presentation constitute forward-looking statements. Such forward-looking statements, including the intended actions and performance objectives of the Fund or the Sponsor referenced herein, involve known and unknown risks, uncertainties, and other important factors that could cause the actual results, performance, or achievements of the Fund or the Sponsor to differ materially.

This material includes projected performance summaries of the Fund's investments. Projections are hypothetical in nature and are shown for illustrative, informational purposes only. They represent potential results based on subjective assessments by the Sponsor of key underlying factors. In calculating the projected returns, the Sponsor has made a variety of estimates and assumptions including, among others, estimates of future operating results, the value of assets and market conditions at the time of disposition, related transaction costs, and the timing and manner of disposition or other realization events. These estimates and assumptions are inherently uncertain and are subject to numerous business, industry, market, regulatory, competitive and financial risks that are outside the control of the Sponsor. Actual operating results, asset values, timing and manner of dispositions or other realization events and resolution of other factors taken into consideration may differ materially from assumptions made by the Sponsor. No representation or warranty is made as to the reasonableness of the assumptions made or that all assumptions used in achieving the returns have been stated or fully considered. Changes in the assumptions may have a material impact on the projected returns presented. Projected returns do not reflect the actual returns of any portfolio and do not guarantee future results.

Subjective Statements. This document includes statements based on the Sponsor's subjective judgements, beliefs and opinions that are subject to change. Other market participants or third parties may have different views or may reach different determinations relating to the investment thesis as described by the Sponsor.

General Usage. Each reference to "we," "our," or other similar plural possessive pronoun used in this presentation shall be deemed to refer solely to the Sponsor as a whole.

Significant Risk. An investment in the Fund involves significant risk, volatility, and illiquidity. There is no guarantee that the Fund's investment objective will be achieved. There is the possibility of loss, and all investment involves risk, including the loss of entire principal.

Your Family Has Already Made a Difference

Vie Offers A Way to Build on It



Disease-focused philanthropy

Grants for research, patient services and advocacy helps lay the groundwork for better treatments.





Vie Ventures

Investment into companies developing promising therapies for people living with autoimmune disease.

A family's commitment to curing a disease remains at the center.


Translating promising science into new therapies.

Breakthrough Science Needs a Path to Patients

Discovery	Development	Approval & Scale
Scientific discovery Promising therapeutic ideas	Preclinical development Early clinical trials Clinical proof of concept	Larger clinical trials Regulatory approval Commercialization
Universities, government, disease philanthropies and industry	**Venture-backed biotech** with development partners	Biotechnology and pharmaceutical companies
~$1-10M	**~$10-100M**	**~$100M-1B**

We Are Entering a New Era in Autoimmune Therapeutics

Tools refined in cancer immunotherapy are opening new possibilities.



Understand the immune system

Engineer more precise therapies

Investigate immune reset and tolerance


CASTLE STUDY: CD19 CAR-T in 24 patients with severe autoimmune disease

Phase 1/2a study in refractory lupus, systemic sclerosis and inflammatory myopathy

Early clinical evidence. Safety, durability and scalability require further study.

Müller et al., Nature Medicine, 7 January 2026. doi:10.1038/s41591-025-04185-6

Breakthroughs for One Disease May Begin in Another



Dupixent: one mechanism, multiple approved indications

A precedent in allergic inflammation that Blocks IL-4 and IL-13 signaling


Atopic dermatitis → Asthma → Eosinophilic esophagitis

Each new indication requires its own clinical evidence.

Dupixent: selected FDA-approved indications, subject to labeling criteria. Source: U.S. prescribing information, 2026.

Invest Broadly. Give with Focus.

An investment engine spanning autoimmune diseases



Invest across autoimmune disease. Seek competitive returns. Build resources for focused philanthropy.

Leadership with Experience, Conviction, and a Compelling Vision



Steven St. Peter, MD

Founder & Managing Director

- Former Managing Director: T1D Fund and MPM Capital
- Former CEO of Aratana Therapeutics
- Physician; company founder and public company CEO



Luke Evnin, PhD

Founder & Managing Director

- Co-founder and former Managing Director: MPM Capital
- Biotechnology company formation and board leadership
- Long-standing Scleroderma Research Foundation leadership



Jeff Bluestone, PhD


Managing Director

- World-class leader in immunology and immune tolerance
- Clinical translation and biotechnology leadership
- Immune Tolerance Network, UCSF, Parker Institute, Sonoma

More than $1B returned to investors while supporting dozens of new therapies

Focused Investment Strategy

Vie Impact plays a catalytic role by enabling initial investments and anchoring I&A Fund



- **Direct investment in companies.**
  - Typically, private companies before exit into public market or M&A.
  - Invest where the biological evidence supports a differentiated therapy.
  - Target advanced-preclinical through Phase 2 where evidence can materially change value
  - Diversify across mechanisms, modalities, and indications while preserving capital to support the strongest companies.
- **Vie Impact as anchor investor in I&A Fund.**
  - Initial investments may later be transferred to I&A Fund.
  - Mobilize larger pools of private capital.

Disease Ecosystem Relationships Can Improve Performance




Collaboration & funding for discovery research



Diligence support



Patient, clinician, & scientist network



Advocacy, regulatory & reimbursement

Vie's Strategic Collaborators

American Diabetes Association.

Arthritis Foundation

BEYOND CELIAC Together for a Cure

complex disorders alliance

CROHN'S & COLITIS FOUNDATION

FASI FOOD ALLERGY SCIENCE INITIATIVE

Immune Boost Capital

MS National Multiple Sclerosis Society

NATIONAL PSORIASIS FOUNDATION

SCLERODERMA RESEARCH FOUNDATION

Sjögren's FOUNDATION

Collaboration Can Improve Investment Outcomes

Teplizumab: complementary contributions at different stages



Scientific innovation
Jeff Bluestone · inventor

Early venture capital
MPM · early investor

Philanthropy
Breakthrough T1D, including T1D Fund as investor

FDA approval in 2022

Bring capabilities together to advance a therapy.

Illustrative historical example. Contributions occurred at different stages and involved many other organizations.

Build the Platform. Demonstrate Execution. Then Scale.

VIE IMPACT

$35M minimum first-close objective → $75M target

First close targeted for early 2027

Initial investments and validation

Potentially 1–2 investments before I&A closes

I&A Fund

~$150M target

Including Vie Impact

Parallel pharma

~$50M target

Prospective strategic capital

~$200M combined investment capacity target

Vie Impact also has a standalone path

Two Ways for Families to Participate

A

PATH A
Give, then invest

Eligible DAF sponsor or family foundation invests charitable assets. Distributions return to that charitable vehicle.

Put existing charitable capital to work.

B

PATH B
Invest, then potentially give

Family invests private assets, intending to contribute future proceeds to a family DAF. The future gift remains voluntary.

Build resources for future philanthropy.

Same investment strategy. Different ownership and charitable timing.

Subject to investor eligibility and applicable DAF sponsor or foundation approval.

A Community Built Around Making Progress

Direct engagement with the science, investments, and people advancing autoimmune therapies.

LEARN FROM THE SCIENCE

Scientific briefings and clinical perspectives from immunologists, physicians, and biotech leaders.

FOLLOW THE INVESTMENTS

Portfolio updates, development milestones, and potential disease-focused co-investment discussions.

CONNECT WITH OTHER FAMILIES

Peer forums, shared disease interests, and opportunities to discuss collaborative philanthropy.

ENGAGE THE NEXT GENERATION

Opportunities for adult children and grandchildren to learn about science, investing, and giving.

Shared purpose. Greater insight. An enduring family legacy.

Mission-Driven. Investment-Disciplined. Personally Aligned

Founding Managing Directors are investing their own capital, contributing to philanthropy, and forgoing cash compensation.

FINANCIAL ALIGNMENT

$10M

at full platform scale

Investment commitment $2.5M at $35M initial Vie Impact close.

Scales to at least $10M at the full ~$200M platform target.

At least half of the launch investment ultimately in philanthropic pools.

PHILANTHROPIC ALIGNMENT

$5–10M

at full platform scale

$5M charitable commitment at the full platform target.

Potentially increases to $10M as Vie Impact gross MOIC reaches 2.0×.

The performance-linked increase is not a guaranteed outcome.

TIME & COMPENSATION

4 YEARS

no founder cash compensation

Founding Managing Directors will not receive salary or cash bonuses during the first four years.

Management resources support the investment team and portfolio execution.

The founders commit capital, time and reputation alongside participants.

Charitable upside depends on Vie Impact performance; amounts and timing remain subject to definitive documentation.

VIE VENTURES

Help Advance the Next Generation of Therapeutics.

Invest Broadly.

Give with Focus.

We are inviting a founding group of families to help establish Vie Impact and build an enduring investment platform for autoimmune disease.